Product Description
Mechanisms of Action: SRC Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: AstraZeneca
Company Location: CAMBRIDGE X0 CB2 0AA
Company CEO: Pascal Soriot
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Germany, Netherlands, United Kingdom, United States
Active Clinical Trial Count: 3
Highest Development Phases
Phase 2: Fibrodysplasia Ossificans Progressiva|Idiopathic Pulmonary Fibrosis|Myositis Ossificans